Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — VantAI, a leading company focused on the…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — VantAI, a leading company focused on the…
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company…
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company…
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and…
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and…
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a…
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a…
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple…
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple…
MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…